Cosmo Pharmaceuticals (OTCMKTS:CMOPF) Stock Price Up 2.1% – Still a Buy?

Cosmo Pharmaceuticals (OTCMKTS:CMOPF)’s stock price rose 2.1% during mid-day trading on Thursday . The company traded as high as C$80.44 and last traded at C$80.44. 40 shares were traded during trading, a decline of 90% from the average daily volume of 403 shares. The stock had previously closed at C$78.79.

Cosmo Pharmaceuticals Stock Performance

The stock has a 50 day simple moving average of C$88.91 and a 200 day simple moving average of C$115.45.

Cosmo Pharmaceuticals Company Profile

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide. The company offers Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Lumeblue (methylene blue MMX), a diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; Uceris/Cortiment, an oral tablet formulation which delivers budesonide directly to the lumen of the colon; Aemcolo/Relafalk, a GI antibiotic with MMX® technology and is approved for the treatment of travellers' diarrhoea; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Eleview, a medical device, which enables the safer and faster removal of colonic lesions; and GI Genius, a system that uses artificial intelligence to detect colorectal polyps during colonoscopy.